The IPOs of MobiKwik, Vishal Mega Mart, and Sai Life Sciences have garnered significant interest, but they show varying levels of investor enthusiasm and grey market premiums (GMPs). Here’s a breakdown:
1. **MobiKwik**: The ₹572 crore IPO has been highly subscribed, with retail interest 26 times over, and a GMP of ₹136. This suggests a potential listing price of ₹415, marking a premium of 48.75%. Its fintech focus offers strong growth potential, making it an attractive option for aggressive investors.
Source:- bbc news
2. **Vishal Mega Mart**: Targeting ₹8,000 crore through its IPO, it saw a moderate response, with retail subscription at 0.52 times. The GMP stands at ₹19, implying a 24.36% premium over the issue price. Being in retail, it offers steady but slower growth compared to fintech.
Source:- news 18
3. **Sai Life Sciences**: With a GMP of ₹31, its IPO indicates a modest 5.65% premium. Despite its NII interest (2.52 times), analysts recommend caution due to its rich valuation compared to peers.
### Recommendation:
– **High-growth potential**: MobiKwik is the top choice for listing gains and long-term scaling.
– **Steady performance**: Vishal Mega Mart is better suited for conservative, long-term investors.
– **Caution advised**: Sai Life Sciences may not offer strong listing gains due to pricing concerns.
Investors should consider their risk appetite and investment horizon before subscribing.
Share your views in the comments
